in partnership with
DRC Logo

Treating AMD

March 13, 2019

There is no cure, or treatment, for dry age-related macular degeneration (AMD) at this time. Individuals diagnosed with advanced wet AMD can receive injections of therapeutic drugs in the eye to slow the progression of vision loss. Patients that are able to receive therapeutic injections will seek treatment with their eye doctor.

Approximately ninety-five percent of AMD patients are diagnosed with dry AMD. Researchers at the Retina Foundation are working diligently to find treatments for these individuals. Funding for this research is a crucial part of discovering treatments. Our AMD research is supported by individuals, foundations, and pharmaceutical/biotechnology corporations.

If you have any questions about clinical trials being conducted at the Retina Foundation, or would like more information, please contact our AMD clinical research staff at amdtrials@rfsw.org.

AMD CLINICAL STUDIES WE ARE CURRENTLY ENROLLING FOR:

Boston Image Reading Center
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03688243
Research Coordinator: Abigail Christie
Phone: 214.363.3911, ext. 118
Study Title: Non Exudative Age-Related Macular Degeneration Imaged With Swept Source Optical Coherence Tomography

Genentech, Inc.
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03972709
Research Coordinator: Renee Denlar
Phone: 214.363.3911, ext. 145
Study Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)

Gyroscope Therapeutics
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03894020
Research Coordinator: Abigail Christie
Phone: 214.363.3911, ext. 118
Study Title: A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

National Eye Institute (NEI)
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03092492
Research Coordinator: Renee Denlar
Phone: 214.363.3911, ext. 145
Study Title: AMD Ryan Initiative Study

Ionis Pharmaceuticals, Inc.
For detailed information go to clinicaltrials.gov/ct2/home: NCT#: 03815825
Research Coordinator: Kimberly Cummings
Phone: 214.363.3911, ext. 128
Study Title: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

 

 

Treating AMD

Related Articles

9th Annual David R. Stager Sr., M.D. Lecture Early Detection and Treatment for Pediatric Eye Conditions – Video Update Gene Causing Blindness Found in Texas Hispanic Families Investigating the Impact of Lazy Eye on Reading Speed and Motor Skills in Children – Video Update Discovering New Therapies for AMD
Mailicon
Get the Latest Updates

Sign up to receive emails from Retina Foundation that will keep you up-to-date on our research and events.

  • This field is for validation purposes and should be left unchanged.
Contact Us

Contact Us

  • This field is for validation purposes and should be left unchanged.
x

Please check all that apply:

How did you learn about the
Retina Foundation?

  • Please check all that apply:
  • This field is for validation purposes and should be left unchanged.
Contact Us

Request an Appointment

Please complete this form if you are interested in speaking to a member of our team about your AMD.

all fields required

DOWNLOAD Printable Form